Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer.

ABSTRACT: Background:We analyzed whether co-occurring mutations influence the outcome of systemic therapy in ALK-rearranged non-small-cell lung cancer (NSCLC). Patients and methods:ALK-rearranged stage IIIB/IV NSCLC patients were analyzed with next-generation sequencing and fluorescence in situ hybridization analyses on a centralized diagnostic platform. Median progression-free survival (PFS) and overall survival (OS) were determined in the total cohort and in treatment-related sub-cohorts. Cox regression analyses were carried out to exclude confounders. Results:Among 216 patients with ALK-rearranged NSCLC, the frequency of pathogenic TP53 mutations was 23.8%, while other co-occurring mutations were rare events. In ALK/TP53 co-mutated patients, median PFS and OS were significantly lower compared with TP53 wildtype patients [PFS 3.9?months (95% CI: 2.4-5.6) versus 10.3?months (95% CI: 8.6-12.0), P?

SUBMITTER: Kron A 

PROVIDER: S-EPMC6225899 | biostudies-literature | 2018 Oct

REPOSITORIES: biostudies-literature